Form 4: Aclaris Therapeutics Director Leonard Braden Michael Increases Stake in Company

Director Leonard Braden Michael reports purchasing additional shares of Aclaris Therapeutics through BML Investment Partners, L.P.

Summary

• On July 2, 2024, Leonard Braden Michael, a director of Aclaris Therapeutics, acquired 86,092 shares of common stock at a weighted average price of $1.144 per share.
• On July 3, 2024, he acquired another 143,288 shares at a weighted average price of $1.159 per share.
• On July 5, 2024, he acquired 123,017 shares at a weighted average price of $1.1489 per share.
• These purchases were made indirectly through BML Investment Partners, L.P., where BML Capital Management, LLC serves as the general partner and Mr. Leonard is the managing member.
• Following these transactions, Mr. Leonard's indirect beneficial ownership in Aclaris Therapeutics increased to 13,447,969 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The director's increased stake suggests confidence, but it's a single transaction and doesn't provide a comprehensive view of the company's health.

Positives

• The director's increased investment could be seen as a positive signal about the company's prospects.

Industry Context

This filing reflects insider trading activity, which is closely monitored by investors for signals about a company's prospects. Increased ownership by a director can be interpreted as a positive sign.

Stakeholder Impact

• Shareholders may view the director's increased stake as a positive signal.

Key Dates